ArticleFrontiers in endocrinology2025
Treatment and outcome of a boy with lgG4-related hypophysitis caused by SARS-CoV-2 re-infection.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Endocrine complications of COVID-19: diabetes, musculoskeletal, thyroid, pituitary, adrenal, and gonadal disorders.Journal of the Endocrine Society · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rationale: SARS-CoV-2 infection can directly and indirectly affect the nervous system, including the hypothalamus and pituitary, and potentially cause IgG4-related hypophysitis. Patient concerns: A 4-year-old Chinese boy presented with arginine vasopressin deficiency (AVP-D, previously called 'central diabetes insipidus') and significant growth retardation. MRI indicated thickening of the pituitary stalk and alterations in the posterior pituitary. Diagnosis: The boy experienced polydipsia, polyuria, and enuresis 4 months after infection by SARS-CoV-2 and 2 months prior to presentation in June 2023. The diagnosis was IgG4-related hypophysitis, AVP-D, and growth hormone deficiency. Treatment with glucocorticoids and desmopressin led to significant resolution of symptoms and normalization of pituitary morphology. However, a second SARS-CoV-2 infection was followed by recurrence of polydipsia, polyuria, and thickening of the pituitary stalk. This recurrence led to a final diagnosis of IgG4-related hypophysitis caused by SARS-CoV-2 infection. Interventions: Glucocorticoids and desmopressin alleviated the AVP-D. Growth hormone and a diet and exercise plan were recommended to manage his short stature. We plan to conduct a functional assessment of the gonadal axis after he is 6 years old. Outcomes: After 18 months, the polydipsia and polyuria were controlled, and an MRI showed significant thinning of the pituitary stalk. This is the first reported case of lgG4-related hypophysitis in a Chinese boy infected with SARS-CoV-2. Lessons: We successfully controlled clinical symptoms, but further follow-up observations are needed to assess recovery. Although the role of SARS-CoV-2 infection in this patient's condition is only suggestive, other reports have described a relationship between SARS-CoV-2 infection and lgG4-related hypophysitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.